Approved MDMA Therapy Services Anticipated To Be Offered In 2024 with Psilocybin Therapy Soon After

April 13 19:23 2023
Nashville Psychedelic Center is currently offering Ketamine therapy. MDMA therapy and Psilocybin therapy are coming soon. The Center provides high-quality psychedelic therapy treatment and related services in the middle Tennessee region.

The Nashville Psychedelic Center is pleased to announce that the Center works with clients to provide significant personal changes with the highly trained and experienced professional team. The organization has experienced the healing power of psychedelic therapy to help others grow and heal. Psychedelic therapy is an emerging and practical field of therapeutic change. The professional staff is excited to work with clients as they progress through their journey of growth and healing.

The Nashville Psychedelic Center serves clients throughout Nashville, Middle Tennessee, or the Southeast region. Clients are encouraged to contact the Center to learn more about the services. Currently, the professional team provides ketamine therapy. In late 2023 or 2024, the Center will offer MDMA therapy, the first new psychedelic therapy since Ketamine. In addition, during the next couple of years, legally guided psilocybin therapy, also known as mushroom therapy, will be available. Legally directed magic mushrooms therapy provides the patient with the benefits of treatment and psychological support.

The professional team works with clients to use psychedelic therapy in their growth journey. Psychedelic therapy helps clients work through loneliness, anxiety, low self-esteem, sadness, feeling stuck, difficulties with direction, lack of correction, past trauma, and much more. KAP (Ketamine-Assisted Psychotherapy) is a unique therapeutic method. KAP is used to address a menu of mental health conditions. These include addiction, chronic pain, PTSD, depression, and anxiety. The use of Ketamine in the therapeutic process enhances and deepens the experience. Psychotherapy and other integrative forms of treatment amplify and prolong the curative effects of Ketamine.

KAP opens a range of doors during the two to three-hour sessions. They include pleasant or difficult ones. The sessions enhance growth, awareness, and insight. In off-label applications, Ketamine is effective for mental health disorders, including depression, anxiety, chronic pain, and post-traumatic stress disorder (PTSD). However, before safely working with Ketamine, medical and psychiatric conditions are assessed. The conditions include hallucinations, chaotic substance use, DID, untreated mania, uncontrolled hyperthyroidism, increased intracranial pressure, cardiovascular disease, cystitis, or evidence of liver disease.

Additional information is available at

MDMA Therapy is the next available option for psychedelic therapy. Research currently shows it to be very effective for treating PTSD and trauma in general. Although it is only in Phase 3 clinical trials with the Multidisciplinary Association for Psychedelic Studies (MAPS), the results are profound and show the value of MDMA as a psychedelic medicine. The Nashville Psychedelic Center has applied to be part of the Expanded Access program and hopes to bring MDMA therapy to Nashville within a year. Robert DeSalvo was the first MAPS-trained therapist in Tennessee and championed psychedelic therapy in the area.

The Nashville Psychedelic Center will be offering psilocybin therapy as part of a psilocybin-assisted psychotherapy course in the next couple of years if the current research and governmental shifts continue on their current paths. Although currently the Center cannot offer psilocybin, the professional team looks forward to helping others heal with this medicine shortly.

An MDMA Assisted Psychotherapy session is around eight hours. Two therapists will be with the client during the session, usually one female and one male. They will follow the MAPS protocol for the experience since research shows it is effective.

In the initial Phase 3 study, 88% of participants with severe PTSD experienced a clinically significant reduction in PTSD diagnostic scores two months after three sessions of MDMA-assisted therapy, compared to 60% of placebo participants. In addition, 67% of participants in the MDMA group, compared to 32% of participants in the placebo group, no longer met the criteria for PTSD remission two months after the sessions.

About the Company: 

The Nashville Psychedelic Center currently offers ketamine-assisted psychotherapy to clients in the Nashville area and throughout the wider region. The Center is awaiting approval for implementing MDMA Assisted Psychotherapy and Psilocybin Therapy. The expectation is that the expansion of psychedelic therapy using MDMA will be launched in late 2023 or in 2024.

Media Contact
Company Name: Nashville Psychedelic Center
Contact Person: Robert DeSalvo or Lindsey Weiner
Email: Send Email
Phone: (615) 560-8742
Address:Berry Hill
City: Nashville
State: TN
Country: United States